Teva Pharmaceutical Industries Limited (TEVA) Stock Rating Lowered by J P Morgan Chase & Co

J P Morgan Chase & Co lowered shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) from a neutral rating to an underweight rating in a report issued on Monday, MarketBeat reports. They currently have $11.00 price objective on the stock, down from their prior price objective of $11.48.

A number of other equities analysts have also recently issued reports on TEVA. Jefferies Group LLC restated a hold rating and issued a $26.00 price objective (down previously from $33.00) on shares of Teva Pharmaceutical Industries Limited in a research report on Wednesday, August 9th. Deutsche Bank AG restated a buy rating and issued a $28.00 price objective (down previously from $43.00) on shares of Teva Pharmaceutical Industries Limited in a research report on Wednesday, August 9th. Sanford C. Bernstein cut shares of Teva Pharmaceutical Industries Limited from an outperform rating to a market perform rating and decreased their price objective for the company from $42.00 to $28.00 in a research report on Friday, August 4th. Cantor Fitzgerald reiterated a neutral rating and set a $27.00 price target (down previously from $31.00) on shares of Teva Pharmaceutical Industries Limited in a research report on Wednesday, August 9th. Finally, Credit Suisse Group reiterated an outperform rating and set a $39.00 price target on shares of Teva Pharmaceutical Industries Limited in a research report on Wednesday, August 9th. Seven equities research analysts have rated the stock with a sell rating, seventeen have given a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of Hold and an average target price of $21.88.

Shares of Teva Pharmaceutical Industries Limited (NYSE TEVA) opened at $12.79 on Monday. Teva Pharmaceutical Industries Limited has a one year low of $10.85 and a one year high of $39.41. The firm has a market cap of $12,801.60, a price-to-earnings ratio of 2.91 and a beta of 0.52. The company has a debt-to-equity ratio of 1.20, a current ratio of 0.96 and a quick ratio of 0.66.

COPYRIGHT VIOLATION NOTICE: “Teva Pharmaceutical Industries Limited (TEVA) Stock Rating Lowered by J P Morgan Chase & Co” was originally posted by BBNS and is the property of of BBNS. If you are viewing this piece of content on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this piece of content can be viewed at https://baseballnewssource.com/markets/teva-pharmaceutical-industries-limited-teva-stock-rating-lowered-by-j-p-morgan-chase-co/1781217.html.

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 12th. Investors of record on Tuesday, November 28th will be issued a dividend of $0.085 per share. The ex-dividend date of this dividend is Monday, November 27th. This represents a $0.34 dividend on an annualized basis and a yield of 2.66%. Teva Pharmaceutical Industries Limited’s payout ratio is -15.80%.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Security National Bank of Sioux City Iowa IA lifted its holdings in Teva Pharmaceutical Industries Limited by 0.4% during the 2nd quarter. Security National Bank of Sioux City Iowa IA now owns 21,788 shares of the company’s stock valued at $724,000 after buying an additional 87 shares in the last quarter. Bronfman E.L. Rothschild L.P. increased its position in Teva Pharmaceutical Industries Limited by 2.6% during the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 3,711 shares of the company’s stock valued at $123,000 after purchasing an additional 94 shares during the period. CIBC Asset Management Inc increased its position in Teva Pharmaceutical Industries Limited by 0.3% during the 2nd quarter. CIBC Asset Management Inc now owns 65,534 shares of the company’s stock valued at $2,177,000 after purchasing an additional 178 shares during the period. Managed Account Services Inc. grew its position in shares of Teva Pharmaceutical Industries Limited by 1.4% in the 2nd quarter. Managed Account Services Inc. now owns 14,911 shares of the company’s stock worth $495,000 after buying an additional 211 shares during the last quarter. Finally, Sheaff Brock Investment Advisors LLC grew its position in shares of Teva Pharmaceutical Industries Limited by 3.6% in the 2nd quarter. Sheaff Brock Investment Advisors LLC now owns 8,389 shares of the company’s stock worth $279,000 after buying an additional 294 shares during the last quarter. Institutional investors own 55.81% of the company’s stock.

Teva Pharmaceutical Industries Limited Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with our FREE daily email newsletter.

 


Latest News

Seattle Mariners Start Offseason With a Bang: Three Trades Over Four Days
Seattle Mariners Start Offseason With a Bang: Three Trades Over Four Days
MLB Commissioner: New Rule for Pace-of-Play in 2018
MLB Commissioner: New Rule for Pace-of-Play in 2018
Alex Cobb Could Be Good Fit for Cubs
Alex Cobb Could Be Good Fit for Cubs
Joey Votto Is One of Baseball’s Best Hitters
Joey Votto Is One of Baseball’s Best Hitters
Hunter Pence May Become Part-Time Player
Hunter Pence May Become Part-Time Player
Perfect 300 Bowled by Red Sox Right Fielder Mookie Betts
Perfect 300 Bowled by Red Sox Right Fielder Mookie Betts


Leave a Reply

 
© 2006-2017 BBNS.